Document is current
Any future updates will be listed below
-
Authors
Aymerich, Claudia https://orcid.org/0000-0003-0040-1608
Salazar de Pablo, Gonzalo https://orcid.org/0000-0002-6992-0767
Pacho, Malein
Pérez-Rodríguez, Violeta https://orcid.org/0000-0002-2485-3054
Bilbao, Amaia
Andrés, Lucía
Pedruzo, Borja
Castillo-Sintes, Idoia
Aranguren, Nerea
Fusar-Poli, Paolo https://orcid.org/0000-0003-3582-6788
Zorrilla, Iñaki
González-Pinto, Ana
González-Torres, Miguel Ángel
Catalán, Ana https://orcid.org/0000-0002-0418-7904
- License Information
-
More Information
Article History
Received: 18 October 2023
Revised: 1 August 2024
Accepted: 5 August 2024
First Online: 22 August 2024
Competing interests
: CA received personal fees or grants from Janssen Cilag and Neuraxpharm outside the current work. GSP has received honoraria from Janssen Cilag, Lundbeck and Angelini outside the current work. PFP has received grant support from Lundbeck and honoraria fees from Angelini, Menarini, and Lundbeck outside the current work. AGP has received grants and served as consultant, advisor or CME speaker for the following entities: Jannsen-Cilag, Lundbeck, Otsuka, Pfizer, Sanofi-Aventis, Exeltis, the Spanish Ministry of Science and Innovation (CIBERSAM), the Ministry of Science (Carlos III Institute), and the Basque Government. AC received personal fees or grants from Lundbeck, ROVI, and Janssen Cilag outside the current work. The rest of the authors reported no biomedical financial interests or potential conflicts of interest.
